Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382010783> ?p ?o ?g. }
- W4382010783 endingPage "813" @default.
- W4382010783 startingPage "813" @default.
- W4382010783 abstract "Importance Psychotic symptoms greatly increase the burden of disease for people with neurodegenerative disorders and their caregivers. Cholinesterase inhibitors (ChEIs) may be effective treatment for psychotic symptoms in these disorders. Previous trials only evaluated neuropsychiatric symptoms as a secondary and an overall outcome, potentially blurring the outcomes noted with ChEI use specifically for psychotic symptoms. Objective To quantitatively assess the use of ChEIs for treatment of individual neuropsychiatric symptoms, specifically hallucinations and delusions, in patients with Alzheimer disease (AD), Parkinson disease (PD), and dementia with Lewy bodies (DLB). Data Sources A systematic search was performed in PubMed (MEDLINE), Embase, and PsychInfo, without year restrictions. Additional eligible studies were retrieved from reference lists. The final search cutoff date was April 21, 2022. Study Selection Studies were selected if they presented the results of placebo-controlled randomized clinical trials, including at least 1 donepezil, rivastigmine, or galantamine treatment arm in patients with AD, PD, or DLB; if they applied at least 1 neuropsychiatric measure including hallucinations and/or delusions; and if a full-text version of the study was available in the English language. Study selection was performed and checked by multiple reviewers. Data Extraction and Synthesis Original research data were requested on eligible studies. A 2-stage meta-analysis was then performed, using random-effects models. Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were followed for extracting data and assessing the data quality and validity. Data extraction was checked by a second reviewer. Main Outcomes and Measures Primary outcomes were hallucinations and delusions; secondary outcomes included all other individual neuropsychiatric subdomains as well as the total neuropsychiatric score. Results In total, 34 eligible randomized clinical trials were selected. Individual participant data on 6649 individuals (3830 [62.6%] women; mean [SD] age, 75.0 [8.2] years) were obtained from 17 trials (AD: n = 12; PD: n = 5; individual participant data were not available for DLB). An association with ChEI treatment was shown in the AD subgroup for delusions (−0.08; 95% CI, −0.14 to −0.03; P = .006) and hallucinations (−0.09; 95% CI, −0.14 to −0.04; P = .003) and in the PD subgroup for delusions (−0.14; 95% CI, −0.26 to −0.01; P = .04) and hallucinations (−0.08, 95% CI −0.13 to −0.03; P = .01). Conclusions and Relevance The results of this individual participant data meta-analysis suggest that ChEI treatment improves psychotic symptoms in patients with AD and PD with small effect sizes." @default.
- W4382010783 created "2023-06-27" @default.
- W4382010783 creator A5007639772 @default.
- W4382010783 creator A5035580474 @default.
- W4382010783 creator A5046841405 @default.
- W4382010783 creator A5066120388 @default.
- W4382010783 date "2023-08-01" @default.
- W4382010783 modified "2023-09-27" @default.
- W4382010783 title "Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease" @default.
- W4382010783 cites W1114757218 @default.
- W4382010783 cites W1494057233 @default.
- W4382010783 cites W1603277425 @default.
- W4382010783 cites W1672491049 @default.
- W4382010783 cites W1872529562 @default.
- W4382010783 cites W1885676552 @default.
- W4382010783 cites W1963583371 @default.
- W4382010783 cites W1964942708 @default.
- W4382010783 cites W1978999542 @default.
- W4382010783 cites W1981706712 @default.
- W4382010783 cites W1983103814 @default.
- W4382010783 cites W1991176470 @default.
- W4382010783 cites W1995412542 @default.
- W4382010783 cites W1996761484 @default.
- W4382010783 cites W2005023775 @default.
- W4382010783 cites W2010076518 @default.
- W4382010783 cites W2020223190 @default.
- W4382010783 cites W2020276351 @default.
- W4382010783 cites W2026376363 @default.
- W4382010783 cites W2029183641 @default.
- W4382010783 cites W2032313795 @default.
- W4382010783 cites W2035556475 @default.
- W4382010783 cites W2048167422 @default.
- W4382010783 cites W2055649795 @default.
- W4382010783 cites W2057245667 @default.
- W4382010783 cites W2064887457 @default.
- W4382010783 cites W2069202115 @default.
- W4382010783 cites W2070653772 @default.
- W4382010783 cites W2075653686 @default.
- W4382010783 cites W2078417280 @default.
- W4382010783 cites W2080212310 @default.
- W4382010783 cites W2082492977 @default.
- W4382010783 cites W2088919930 @default.
- W4382010783 cites W2107895214 @default.
- W4382010783 cites W2112710171 @default.
- W4382010783 cites W2113839148 @default.
- W4382010783 cites W2115455636 @default.
- W4382010783 cites W2117134611 @default.
- W4382010783 cites W2125435699 @default.
- W4382010783 cites W2125458229 @default.
- W4382010783 cites W2138338009 @default.
- W4382010783 cites W2143879671 @default.
- W4382010783 cites W2152370183 @default.
- W4382010783 cites W2155156351 @default.
- W4382010783 cites W2158609513 @default.
- W4382010783 cites W2161016232 @default.
- W4382010783 cites W2163302570 @default.
- W4382010783 cites W2168956122 @default.
- W4382010783 cites W2255366821 @default.
- W4382010783 cites W2276024626 @default.
- W4382010783 cites W2461890752 @default.
- W4382010783 cites W2534984889 @default.
- W4382010783 cites W2623521763 @default.
- W4382010783 cites W2769541324 @default.
- W4382010783 cites W2799828859 @default.
- W4382010783 cites W2914562195 @default.
- W4382010783 cites W2945624955 @default.
- W4382010783 cites W2951808807 @default.
- W4382010783 cites W2970684805 @default.
- W4382010783 cites W3031549057 @default.
- W4382010783 cites W3092227888 @default.
- W4382010783 cites W3147485225 @default.
- W4382010783 cites W3173809143 @default.
- W4382010783 cites W3184714752 @default.
- W4382010783 cites W4226359030 @default.
- W4382010783 cites W4229844344 @default.
- W4382010783 doi "https://doi.org/10.1001/jamaneurol.2023.1835" @default.
- W4382010783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37358841" @default.
- W4382010783 hasPublicationYear "2023" @default.
- W4382010783 type Work @default.
- W4382010783 citedByCount "0" @default.
- W4382010783 crossrefType "journal-article" @default.
- W4382010783 hasAuthorship W4382010783A5007639772 @default.
- W4382010783 hasAuthorship W4382010783A5035580474 @default.
- W4382010783 hasAuthorship W4382010783A5046841405 @default.
- W4382010783 hasAuthorship W4382010783A5066120388 @default.
- W4382010783 hasConcept C118552586 @default.
- W4382010783 hasConcept C126322002 @default.
- W4382010783 hasConcept C142724271 @default.
- W4382010783 hasConcept C15744967 @default.
- W4382010783 hasConcept C168563851 @default.
- W4382010783 hasConcept C17744445 @default.
- W4382010783 hasConcept C199539241 @default.
- W4382010783 hasConcept C204787440 @default.
- W4382010783 hasConcept C27081682 @default.
- W4382010783 hasConcept C2776332859 @default.
- W4382010783 hasConcept C2777466982 @default.
- W4382010783 hasConcept C2778548049 @default.
- W4382010783 hasConcept C2779056891 @default.